Azenta, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Azenta (AZTA) announced CEO John Marotta's resignation and appointed Dr. Martin Madaus as interim CEO. The company reaffirmed its Q4 2026 revenue guidance of 3-5% growth. Analysts discuss potential impacts on margins and profitability during the leadership transition.
Funko (FNKO) rose 4.9% after Seaport Research initiated coverage with a Buy rating and $8 target. Hims & Hers Health (HIMS) fell 9.2% due to Visa's Acquirer Monitoring Program enrollment. Azenta (AZTA) dropped 9.1% following CEO John Marotta's resignation. Strategy (MSTR) gained 4.8% after raising $2.01B in equity sales. RUM Group (RUM) increased 6% after a $13.7B AI chip contract.
Azenta (AZTA) stock fell 10.4% after CEO John Marotta resigned. Interim CEO Dr. Martin Madaus was appointed. Q4 adjusted EBITDA will include a $3M consulting charge. Revenue guidance was reaffirmed. The Nasdaq Composite was down 0.7%.
Over the past 7 days, alphai's AI scored 5 news stories mentioning AZTA (Azenta, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent AZTA coverage spans corporate actions, earnings and market movers.
In the last 30 days, AZTA insiders filed 1 SEC Form 4 transaction — 1 purchase ($8K) and no sales. The most active reporter was Starr Ephraim, SVP, Gen Counsel & Secretary, with 1 filing.
Interim leadership may increase execution risk and affect margin initiatives, potentially pressuring the stock in the short term.
Leadership change creates uncertainty.
The abrupt leadership change creates uncertainty and a near-term price decline.
Leadership change may cause short‑term volatility and affect execution of strategic initiatives.
The call provides a fresh FY2026 outlook range plus operational updates (Multiomics turnaround, automated store remediation, AI-enabled biorepository deployment) that can drive near-term estimate revisions.
alphai scores every news story that mentions AZTA with an AI model for sentiment and relevance, and aggregates insider trades from Azenta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azenta (AZTA) announced CEO John Marotta's resignation and appointed Dr. Martin Madaus as interim CEO. The company reaffirmed its Q4 2026 revenue guidance of 3-5% growth. Analysts discuss potential impacts on margins and profitability during the leadership transition.
2 min readFunko (FNKO) rose 4.9% after Seaport Research initiated coverage with a Buy rating and $8 target. Hims & Hers Health (HIMS) fell 9.2% due to Visa's Acquirer Monitoring Program enrollment. Azenta (AZTA) dropped 9.1% following CEO John Marotta's resignation. Strategy (MSTR) gained 4.8% after raising $2.01B in equity sales. RUM Group (RUM) increased 6% after a $13.7B AI chip contract.
2 min readAzenta (AZTA) stock fell 10.4% after CEO John Marotta resigned. Interim CEO Dr. Martin Madaus was appointed. Q4 adjusted EBITDA will include a $3M consulting charge. Revenue guidance was reaffirmed. The Nasdaq Composite was down 0.7%.
2 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. AZENTA ANNOUNCES LEADERSHIP TRANSITION Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., August 24, 2026 – Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”) to
2 min readAzenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.
7 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02(c) On August 6, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Erik J. Bello, age 51, as the Company’s Vice President, Chief Accounting Officer, effective upon the commencement of his employment with the Company, which is expected t
2 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains, while noting uneven leadership hurt quality-focused strategies. The firm said it sold Azenta, Inc. (NASDAQ:AZTA) after execution issues, weaker life sciences funding, and softer capital equipment demand led management to lower its full-year outlook. Azenta closed Aug. 5 at $31.82.
4 min readStarr Ephraim (SVP, Gen Counsel & Secretary) purchased 335 shares of Azenta, Inc. (AZTA) at $24.17 on 2026-07-31.
1 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026. The results of B Medical Systems are r
6 min readAzenta (NASDAQ:AZTA) will report Q2 results Tuesday after the bell. The company missed prior-quarter revenue and EPS expectations, with revenue at $144.8 million, flat year on year. For Q2, analysts expect revenue up 3.7% y/y. The stock is up 9.6% over the past month, with an average price target of $27.80 versus $28.13.
3 min read
